Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has signed an agreement with Zumutor Biologics, Inc., to manufacture Zumutor’s lead candidate, ZM008, for the treatment of solid tumors. Zumutor is a biologics company that develops novel immuno-oncotherapeutics to drive transformational improvements in cancer treatment.

ZM008 is a first-in-class monoclonal antibody targeting tumor cell receptors that block natural killer (NK) cell inhibitory signals and enables NK cell activation to generate a potent immune response. NK cells are a type of cytotoxic lymphocyte (white blood cell) and are a critical component in the innate human immune system, which ZM008 can utilize to target solid tumor cells for diseases such as prostate cancer.

“We were able to fast track the development of ZM008 by leveraging INABLR, our proprietary antibody discovery platform,” stated Kavitha Iyer, Founder & CEO of Zumutor Biologics. “Robust preclinical data for ZM008 demonstrates tumor cell death, immune cell infiltration, and tumor growth inhibition. In vivo studies demonstrate anti-tumor efficacy as a monotherapy or in combination with immune checkpoint inhibitors. Development is on track for investigational new drug filing by the end of 2020, and we have placed our trust in Catalent to deliver on-time and with the highest quality in true partnership.”

Please read the full article at the links below: